ArticleVaccine2010
Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines.
Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase.PLoS pathogens · 2026Article
- Phylogenetic Analysis, Morphological Characteristics, and Cellular Tropism of Vaccine-Like Recombinant Strains of Lumpy Skin Disease Virus in China.Transboundary and emerging diseases · 2025Article
- Kaposi sarcoma-associated herpesvirus complement control protein (KCP) and glycoprotein K8.1 are not required for viral infectionJournal of virology · 2024Article
- Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform.NPJ vaccines · 2024Article
- Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice.Frontiers in immunology · 2024Article
- Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages.Frontiers in immunology · 2024Article
- Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice.Pathogens (Basel, Switzerland) · 2023Article
- Evaluation of the Effect of CD70 Co-Expression on CD8 T Cell Response in Protein-Prime MVA-Boost Vaccination in Mice.Vaccines · 2023Article
- Article
- Methods for measuring the evolutionary stability of engineered genomes to improve their longevity.Synthetic biology (Oxford, England) · 2021Article
- Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform.Nature communications · 2020Article
- Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.Research square · 2020Article
- Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine.bioRxiv : the preprint server for biology · 2020Article
- The Status of Vaccine Development Against the Human Cytomegalovirus.The Journal of infectious diseases · 2020Review
- A new oncolyticJournal for immunotherapy of cancer · 2020Article
- Article
- Article
- Article
- Generation of recombinant MVA-norovirus: a comparison study of bacterial artificial chromosome- and marker-based systems.Virology journal · 2019Article
- Recombinant vector vaccine evolution.PLoS computational biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
We have engineered recombinant (r) Modified Vaccinia Ankara (MVA) to express multiple antigens under the control of either of two related vaccinia synthetic promoters (pSyn) with early and late transcriptional activity or the modified H5 (mH5) promoter which has predominant early activity. We sequentially passaged these constructs and analyzed their genetic stability by qPCR, and concluded that rMVA expressing multiple antigens using the mH5 promoter exhibit remarkable genetic stability and maintain potent immunogenicity after serial passage. In contrast, rMVA expressing antigens using engineered vaccinia synthetic E/L (pSyn I or II) promoters are genetically unstable. Progressive accumulation of antigen loss variants resulted in a viral preparation with lower immunogenicity after serial passage. Metabolic labeling, followed by cold chase revealed little difference in stability of proteins expressed from mH5 or pSyn promoter constructs. We conclude that maintenance of genetic stability which is achieved using mH5, though not with pSyn promoters, is linked to timing, not the magnitude of expression levels of foreign antigen, which is more closely associated with immunogenicity of the vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.